Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01235962 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

A Phase 3 study of Cancer and Renal Cell Carcinoma (RCC), sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
1,538
Enrollment target
20
Study locations

NCT01235962: Completed Phase 3 study of Cancer and Renal Cell Carcinoma (RCC), sponsored by Novartis Pharmaceuticals.

NCT01235962 is a Phase 3 study of Cancer and Renal Cell Carcinoma (RCC) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,538 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01235962, a Phase 3 study of Cancer and Renal Cell Carcinoma (RCC), has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
1,538 participants
Enrollment target
20
Study locations

Study Summary

This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

Primary Outcome

DFS is defined as the interval between the date of randomization and the earliest date of disease recurrence/metastasis or death due to any cause.

Conditions Studied

Cancer Renal Cell Carcinoma (RCC)

Interventions

  • DRUG placebo
  • DRUG pazopanib

Study Locations (20)

California

  • Novartis Investigative Site - Antioch
  • Novartis Investigative Site - Beverly Hills
  • Novartis Investigative Site - Fresno
  • Novartis Investigative Site - La Jolla
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Oakland
  • Novartis Investigative Site - Sacramento
  • Novartis Investigative Site - San Francisco
  • Novartis Investigative Site - South San Francisco
  • Novartis Investigative Site - Stanford
  • Novartis Investigative Site - Vallejo

Florida

  • Novartis Investigative Site - Fort Myers
  • Novartis Investigative Site - Tampa

Georgia

  • Novartis Investigative Site - Athens
  • Novartis Investigative Site - Macon

Arkansas

  • Novartis Investigative Site - Jonesboro

Colorado

  • Novartis Investigative Site - Fort Collins

District of Columbia

  • Novartis Investigative Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,538 participants
Start Date 2010-11-30
Est. Completion 2019-04-15
Phase Phase 3
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT01235962 record still lists

NCT01235962 is an interventional study that assigns participants to a tested intervention. Its 1,538 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (56% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01235962 names 20 study sites across 6 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01235962 about?

NCT01235962 is a clinical study titled "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)". This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

What is the current status of trial NCT01235962?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2010-11-30. Estimated completion is 2019-04-15.

What conditions does trial NCT01235962 study?

This clinical trial studies the following conditions: Cancer, Renal Cell Carcinoma (RCC).

What interventions are being tested in trial NCT01235962?

The interventions under investigation include: placebo (DRUG), pazopanib (DRUG).

Who is sponsoring clinical trial NCT01235962?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01235962 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01235962's enrollment target sits among peer trials

1,538 67th of 615 higher than 549 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06842875 · 1,536 participants · NA

    Rhode Island - Statewide Postpartum Hypertension Remote Surveillance

  • NCT03435796 · 1,541 participants · Phase 2

    Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  • NCT06729775 · 1,546 participants · NA

    Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back

  • NCT06393374 · 1,530 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01235962, the US trial registry maintained by the National Library of Medicine. NCT01235962 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.